Article thumbnail

Kinome expression profiling and prognosis of basal breast cancers

By Renaud Sabatier, Pascal Finetti, Emilie Mamessier, Stéphane Raynaud, Nathalie Cervera, Eric Lambaudie, Jocelyne Jacquemier, Patrice Viens, Daniel Birnbaum and François Bertucci
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. A gene-expression signature as a predictor of survival in breast cancer.
  2. (2010). A: Identification of subtypes in human epidermal growth factor receptor 2–positive breast cancer reveals a gene signature prognostic of outcome.
  3. (2005). An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA
  4. (2007). An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol
  5. (2007). Bhanot G: High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res
  6. (2003). Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA
  7. (2006). BørresenDale AL: Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.
  8. (2008). C: A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer. Breast Cancer Res
  9. (2006). Cell-type specific gene expression profiles of leukocytes in human peripheral blood.
  10. (1998). Cluster analysis and display of genome-wide expression patterns.
  11. (2009). de Vijver MJ: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.
  12. (2005). Etten RA: Tyrosine kinases as targets for cancer therapy.
  13. (2011). F: A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat
  14. (2008). F: Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. Cancer Res
  15. (2005). Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet
  16. (2011). Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat
  17. (2006). Gene expression profiling and clinical outcome in breast cancer. Omics
  18. (2006). Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
  19. (2009). Gene expression profiling of breast cancer.
  20. (2006). Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene
  21. (2005). Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res
  22. (2008). How basal are triple-negative breast cancers?
  23. (2009). Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res
  24. (2007). Iggo RD: Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol
  25. (2010). Immune regulation of cancer.
  26. Ingenuity Pathways Analysis v8.0-2602
  27. (2006). L: Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
  28. (2006). LD: Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res
  29. (2008). Lopez-Guillermo A, et al: Stromal gene signatures in large-B-cell lymphomas.
  30. (2002). López-Guillermo A, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
  31. (2005). Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA
  32. (2000). Molecular portraits of human breast tumours. Nature
  33. (2004). MR: A census of human cancer genes. Nat Rev Cancer
  34. (1993). P: FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chromosomes Cancer
  35. (2009). Park KH: Immunomodulation of Breast Cancer via Tumor Antigen Specific Th1. Cancer Res Treat
  36. (2006). Perou CM: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics
  37. (2002). SH: Gene expression profiling predicts clinical outcome of breast cancer.
  38. (2008). Sotiriou C: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res
  39. (2003). Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics
  40. (2005). Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics: Reporting recommendations for tumor marker prognostic studies.
  41. (2002). Sudarsanam S: The protein kinase complement of the human genome. Science
  42. (2009). Sültmann H: Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat
  43. (2009). T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res
  44. (2007). Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat rev cancer
  45. (2007). TRANSBIG Consortium: Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res
  46. (2010). Triche TJ: Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children’s oncology group.
  47. (2009). Use of tumour-responsive T cells as cancer treatment. Lancet